In the presentation Paul did mention the cash on hand at the end of the last quarter stating we should be fully funded to the end of P3 trials. However he then went on to say that if this wasn't the case ( possibly due to the increase in size that was not covered) they would address the situation towards the end of the trial. Axe could your question read:
... please explain the rational and is the company still fully funded for an expanded P3 trial or will more funds be required towards the end? If so how will that money be raised eg part of a distribution deal, SPP etc?
In the presentation Paul did mention the cash on hand at the end...
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.040(15.1%) |
Mkt cap ! $78.80M | |||
| Open | High | Low | Value | Volume |
| 26.5¢ | 26.5¢ | 22.0¢ | $503.0K | 2.101M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 210000 | 2 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |